MET and VEGF: synergistic targets in castration-resistant prostate cancer
about
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapyThe treatment landscape in thyroid cancer: a focus on cabozantinibThe best of both worlds - managing the cancer, saving the bone.Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapyCabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation studyPhase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.Controlling escape from angiogenesis inhibitors.Bevacizumab treatment of prostate cancer.Cell mates: paracrine and stromal targets for prostate cancer therapy.Bevacizumab for glioblastoma-a promising drug or not?Development of cabozantinib for the treatment of prostate cancer.A phase I study of cabozantinib (XL184) in patients with renal cell cancer.Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin.Pao Pereira Extract Suppresses Castration-Resistant Prostate Cancer Cell Growth, Survival, and Invasion Through Inhibition of NFκB Signaling.Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.Cabozantinib as a novel therapy for renal cell carcinoma.
P2860
Q26741450-995925B3-424A-4EC7-9186-C41386A4B06BQ26796404-B9760FA8-8FD7-4947-B999-BED68F02511FQ33920055-670EBA44-F177-4D3D-9A78-1BA9E74A428FQ33946929-F97F2DF4-3D7E-4471-9B77-C4E931840760Q34253081-0373A95C-31A4-428C-8F94-374B8735B59EQ34330748-5C93D21D-D677-46AF-AEB8-F36218DF5511Q35181099-89D8A0F7-5A13-4321-9D73-35101E4BDCBDQ36436763-4404FF7D-FBFB-4ABE-A03C-DE748E6D0F12Q36828371-26F0B21A-551F-4A6A-AA80-7A8E26DFB953Q37341918-4F9BF008-8699-42E9-88ED-10D788306224Q37655079-585B76E0-52DA-4AB9-8B6F-15290BC56DA7Q37672654-D95A3AA9-5627-4D46-ACAF-03CD7BD3DE76Q38024852-0162B627-1825-4C2E-ADA1-CF27F3A390A6Q38121792-510CE814-81C2-4E9B-8A7C-333C15AF7EFBQ38161401-5920A21A-200D-46DA-B44A-5BAB53CBF036Q38208820-81C8DD38-61BE-4BE7-AA16-73172AAEF0B6Q38430335-58993667-45A6-423A-B3AE-B4D7368B2C2AQ39042430-D47A241F-8DF7-4BB3-8B81-1C3201A3C8CCQ39052394-46BB0801-845A-49EE-BAED-BB4600D7B225Q39085630-269DB556-A16D-43A6-9891-D28C66017689Q39490838-5168A373-980F-4FD7-9323-27591C47B4D6
P2860
MET and VEGF: synergistic targets in castration-resistant prostate cancer
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
MET and VEGF: synergistic targets in castration-resistant prostate cancer
@ast
MET and VEGF: synergistic targets in castration-resistant prostate cancer
@en
type
label
MET and VEGF: synergistic targets in castration-resistant prostate cancer
@ast
MET and VEGF: synergistic targets in castration-resistant prostate cancer
@en
prefLabel
MET and VEGF: synergistic targets in castration-resistant prostate cancer
@ast
MET and VEGF: synergistic targets in castration-resistant prostate cancer
@en
P2860
P1476
MET and VEGF: synergistic targets in castration-resistant prostate cancer
@en
P2093
D M McDonald
P2860
P2888
P304
P356
10.1007/S12094-011-0719-5
P577
2011-10-01T00:00:00Z